Pramlintide is a synthetic analogue of the pancreatic hormone amylin, approved by the FDA as an adjunct to insulin therapy in adults with type 1 or type 2 diabetes, and investigated for weight management due to amylin's central role in meal-related satiety signaling. Amylin is co-secreted with insulin from pancreatic beta-cells and slows gastric emptying, suppresses post-meal glucagon release, and activates satiety circuits in the area postrema and nucleus tractus solitarius of the brainstem. Randomized controlled trials demonstrate that subcutaneous pramlintide administration before meals significantly reduces 24-hour caloric intake, meal sizes, and body weight in obese subjects, with effects independent of glycemic control. Pramlintide is an FDA-approved prescription medication (Symlin); its weight management application is off-label in non-diabetic patients, and use requires monitoring for hypoglycemia, particularly when co-administered with insulin. Pramlintide vs cagrilintide: the amylin analogue generation gap Pramlintide (Symlin) is a first-generation amylin analogue with a short half-life requiring injection before each meal. Per FDA labeling, the maintenance dose is 30–60 mcg per meal for type 1 diabetes and 120 mcg per meal for type 2 diabetes. Cagrilintide, currently in Phase 3 development, is a long-acting amylin analogue designed for once-weekly subcutaneous administration, combining with semaglutide in the CagriSema combination. Cagrilintide's weekly dosing removes this barrier and enables combination with a weekly GLP-1 agonist in a single injection protocol. Pramlintide for weight management: In adults without diabetes, pramlintide produces modest mean weight reductions of 3–5% over 6-month studies — less than GLP-1 agonists but with a complementary mechanism. Some researchers have combined pramlintide with a GLP-1 agonist (pramlintide + GLP-1) as an early-generation dual amylin/incretin approach, reporting additive weight reductions. CagriSema (cagrilintide + semaglutide) in Phase 3 represents the pharmacologically optimised version of this dual approach, with superior efficacy and weekly dosing. Pramlintide's practical role in new weight management programs has therefore narrowed significantly as cagrilintide and GLP-1/amylin combinations approach approval.